Belluscura (FRA:9VQ) Capital Expenditure : €-5.87 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Belluscura Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Belluscura's cash flow for capital expenditures for the six months ended in Jun. 2023 was €-2.01 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2023 was €-5.87 Mil.

Belluscura Capital Expenditure Historical Data

The historical data trend for Belluscura's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Capital Expenditure Chart

Belluscura Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Capital Expenditure

-0.71

-1.01

-0.98

-2.47

-4.79

Belluscura Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Capital Expenditure	Get a 7-Day Free Trial				-0.94	-1.47	-0.94	-3.86	-2.01

Belluscura Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-5.87 Mil.

Belluscura (FRA:9VQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

BELL:UK

Address

15 Fetter Lane, Holborn, London, GBR, EC4A 1BW

Website

https://www.belluscura.com

Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines